MEDICAL DIAGNOSTIC TECHNOLOGY
Speclipse, Inc. has developed a transformative, patented technology for real-time, non-invasive, in-vivo cancer diagnosis utilizing laser spectroscopy and machining learning algorithms.
Clinical trials in the United States, Australia, and South Korea have shown a skin-cancer diagnostic accuracy rate of greater than 90%, higher than any other competing technologies that have attempted to achieve a similar clinical outcome. Diagnostic tools presently used by physicians such as dermascopes or confocal microscopes, provide 60-70% accuracy, far below that of Spectra-Scope®.
Speclispe, Inc. has acquired ISO134485 certification for its manufacturing facility, and Specta-Scope® is on-track, expected to obtain CE mark and TGA approval in early 2019.
Speclipse was founded by three Stanford University graduates and a dermatologist in November 2015, and currently has offices in Silicon Valley, California and South Korea. Speclipse’s technology was first developed in conjunction with a South Korean national lab, KIMM (Korea Institute of Machinery and Materials), and Seoul National University Hospital. Speclipse raised $3M in November 2016 and is planning for commercial launch of their Spectra-Scope® product in 2019.
Speclipse’s core diagnostic technology is available in two models. Spectra-Scope® is an “add-on module” which can be attached to existing aesthetic lasers at dermatology or primary care clinics to provide instant skin cancer diagnosis. The second diagnostic model offered is a “stand-alone” system which can be used without any additional equipment or accessories. It can be used by medical or cosmetic clinics who do not have existing laser equipment, or who prefer a small, portable stand-alone device for real-time diagnosis.
Due to the instantaneous nature and high-accuracy results provided by this technology, it is valuable for use in pathology labs for diagnosing biopsy samples, and beneficial for real-time diagnosis during oncological surgeries as well.
Besides its outstanding clinical benefit, Spectra-Scope’s® size and portability make it uniquely qualified to address the unmet need for a technology which provides diagnostic accuracy and real-time results, with a cost-effective and minimal footprint.
Chief Executive Officer
Sung Hyun Pyun
Former Senior Engineer, KIMM
Former Consultant, The Boston Consulting Group
M.S. / Ph.D. in ME, Stanford University (Advanced Laser Diagnostics and Shock Tube Lab)
B.S. in ME, KAIST
Chief Technology Officer
M.S. in ME, Stanford University (Advanced Laser Diagnostics and Shock Tube Lab)
B.S in ME, Seoul National University
Extensive experiences on laser sensor development
Chief AI Officer
Minsan Ko, PhD
Assistant professor of ICT dept., Hanyang University
Former data scientist at AIRI
Former data scientist at Samsung
M.S., Ph.D. in Computer Science, KAIST
Chief Medical Officer
Head, Naeum Dermatology and Aesthetic Clinic
Medical Director, Lutronic, Inc.
M.D., Ph.D. in Yonsei Univ.
VP of US Business
Former Lead Engineer, 1366 Technologies, Inc.
Ph.D. in ME, Massachusette Institute of Technology (Varanasi Group)
M.S. in ME, Stanford University (Microfluidics Lab)
B.S in ME, Seoul National University
Professor of Dermatology, SNU Hospital
M.D., Ph.D. in SNU
PD/FDA Process Advisor
Project Manger at Johnson & Johnson
20+ year of FDA Class II device development
President of Silicon Valley at LS Corp.
Former CTO at GE Healthcare
Ph.D. in ME, Stanford University
Markcity Orange #502
123, Unjung-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
310 De Guigne Dr
Sunnyvale, California 94085 USA
For any inquiries,
Please call or e-mail us: